What the studies show
It darkens skin reliably — that is its mechanism, and hyperpigmentation is the expected effect in every trial. What has never been studied is the safety of using it for cosmetic tanning in healthy people, and no regulator has approved that use.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria.N Engl J Med, 2015Two phase 3 trials; EU n=74, US n=94.
In context
Afamelanotide is a linear analogue of the pigment hormone α-MSH, developed in the 1980s as the first 'Melanotan'. It is an approved medicine — as a subcutaneous implant replaced every two months — for erythropoietic protoporphyria, a genetic disorder in which sunlight causes severe pain within minutes. In two randomised trials it roughly doubled the hours patients could spend in direct sun without pain. The same molecule is sold illegally as a tanning injection; for that use there is no approval and no controlled evidence of safety.
Afamelanotide (Melanotan I) is approved (rx) — erythropoietic protoporphyria. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Afamelanotide (Melanotan I) proven to help with skin pigmentation?
What studies are behind the grade?
Is Afamelanotide (Melanotan I) approved for this?
Other outcomes for Afamelanotide (Melanotan I)
- APain-free sun exposure in erythropoietic protoporphyria2 phase 3 RCTs (EU n=74, US n=94)
- CVitiligo repigmentationSmall RCTs with phototherapy
- AAdverse effectsadversePhase 3 + registry
Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →